Company intelligence / Profile preview

Signal12 Inc.

Greenwich, Connecticut, USAsignal12inc.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Signal12’s lead program, Pro‑ocular™, is a first-in-class, drop-free topical gel that targets the ophthalmic branch of the trigeminal nerve via transappendageal delivery. In three completed Phase 2 studies—including in oGvHD and Sjögren’s syndrome—Pro‑ocular™ demonstrated statistically significant improvements in both signs and symptoms of disease, with benefits maintained over a two-year extension. The company has secured FDA alignment on its pivotal Phase 3 trial design for oGvHD and is actively raising capital to advance development.

Therapeutic areas: ImmunologyOphthalmology
Modalities: Topical gel via transappendageal forehead delivery
Industry: Biotech

Drug pipeline

1 asset

Pro-ocular

Phase 3

Indications: Ocular Graft-versus-Host Disease, Dry Eye Disease

Partnerships

Spencer Trask & Co.

Beyond the preview

Go deeper on Signal12 Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signal12 Inc..